ABSTRACT

Despite recent advances in early screening and chemotherapeutic intervention, prostate cancer remains a leading cause of cancer-related deaths in men in the United States. Thus, there exists a critical need to investigate and develop novel molecular strategies for the treatment of prostate cancer. Recent data revealed that suppressor of cytokine signaling proteins, SOCS1 and SOCS3, are potentially promising targets for the treatment of prostate cancer. Suppressor of cytokine signaling proteins are a family of negative feedback regulators that inhibit signal transduction pathways following activation from numerous cytokines, growth factors, and hormones. Additional studies are needed to reveal underlying genetic interactions controlling the anticancer effects observed in the experimental investigations highlighted in this review. The current review article is designed to focus on contemporary experimental evidence demonstrating the clinical significance of SOCS1 and SOCS3 in prostate cancer. Future research focusing on SOCS1 and SOCS3may elucidate officinal strategies to effectively attenuate prostate cancer cell growth. Keywords: SOCS1, SOCS3, Negative regulator, Signal transduction, Prostate cancer

https://ijbpas.com/pdf/2018/March/1519918206MS IJBPAS 2018 4378.pdf

Download PDF